SCHEMBL6772307

SCHEMBL6772307

COc1ccc(-c2ccc(S(=O)(=O)NC3CC(CSc4nc[nH]n4)OC3=O)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NAAA Q02083 1/20 0.39
HPGD P15428 1/20 0.39
POLB P06746 2/20 0.36
TP53 P04637 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36
PTGDR Q13258 1/20 0.35
MMP2 P08253 4/20 0.35
MMP9 P14780 3/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
MEP1B Q16820 1/20 0.34
MMP1 P03956 2/20 0.33
MMP3 P08254 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768634 0.82 CA12 (0.43) ALDH1A1LMNASMN1; SMN2NAAAHPGD
SCHEMBL6773324 0.78 HSD11B1 (0.39) ALDH1A1LMNASMN1; SMN2NAAAHPGD
SCHEMBL6768648 0.77 KCNA5 (0.43) ALDH1A1LMNASMN1; SMN2NAAAHPGD
SCHEMBL6771937 0.77 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2HPGDPOLB
SCHEMBL6771966 0.74 ALDH1A1 (0.44) ALDH1A1LMNASMN1; SMN2NAAAHPGD
SCHEMBL6772860 0.72 MMP2 (0.39) ALDH1A1HPGDPTGDRMMP2MMP9
SCHEMBL6772326 0.65 MMP2 (0.50) MMP2MMP9MMP1MMP3MMP13
SCHEMBL6774604 0.62 NPC1 (0.40) ALDH1A1LMNASMN1; SMN2NAAAHPGD
SCHEMBL6248367 0.59 CYP1A2 (0.50) ALDH1A1SMN1; SMN2HPGDPOLBTP53
SCHEMBL18780384 0.58 MAPT (0.46) ALDH1A1LMNASMN1; SMN2HPGDMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0861281-B1 Thermosetting bismaleimide polymer for composite and adhesive applications CYTEC TECH CORP (US) 2002-06-05 EP claimed
US-6762198-B2 SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID THE PROCTER & GAMBLE COMPANY 2004-07-13 US disclosed
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-12-04 US disclosed
US-6566381-B1 For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease THE PROCTER & GAMBLE COMPANY 2003-05-20 US disclosed
EP-1165530-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-01-02 EP disclosed
WO-2000051993-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors ADAM9, ADAM17, ADAM8 ALDH1A1 966/4885LMNA 2052/4885SMN1; SMN2 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.